News
Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO
Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following the company’s decision to trim its 2025 financial outlook.
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
The appointment came shortly after Novo slashed its financial forecast, predicting this year’s sales will grow 8% to 14%, ...
Novo Nordisk’s plummet is a warning for backers who’ve crowded into a relatively small group of very large stocks.
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.
5hon MSN
Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...
The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...
While Ozempic is effective at treating type 2 diabetes and supporting weight loss, it can also come with side effects.
On Tuesday, Novo took an axe to its financial outlook in a surprise corporate update call where it replaced its CEO with an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback